Evolocumab significantly lowers atherogenic lipoprotein particles (LDL-P), including low-density and remnant lipoproteins, a recent study found. The post-hoc sub-analysis included 619 patients from the DECARTES trial, a 52-week, randomized, double-blind, placebo-controlled, global study of patients with hyperlipidemia. At baseline, mean LDL-P concentration was 1,077 nmol/L for the placebo group and 1,100 nmol/L for the evolocumab group. Researchers found:
- In patients receiving evolocumab, week 52 total LDL-P concentration decreased to 610 nmol/L, a treatment difference of 50% vs placebo.
- Evolocumab also reduced concentrations of medium VLDL-P, small VLDP-P, and IDL-P.
- Mean changes in total LDL particle size in the evolocumab group was ‒1.7.
- Changes in total LDL, HDL, and VLDL particle sizes were all significant vs placebo.
Toth PP, Sattar N, Blom DJ, et al. Effect of evolocumab on lipoprotein particles. [Published online ahead of print November 8, 2017]. Am J Cardiol. doi:10.1016/j.amjcard.2017.10.028.
This Week's Must Reads
Length of Stay & Early Discharge After Acute MI, Am J Cardiol; ePub 2017 Nov 22; Tran, et al
SBP Response and Discordant Trial Results, J Am Heart Assoc; ePub 2017 Nov 13; Huang, et al
Racial Differences in Natriuretic Peptide Levels, JAMA Cardiol; ePub 2017 Nov 22; Bajaj, et al
Gender Disparities in Cardiovascular Testing, J Am Heart Assoc; ePub 2017 Nov 29; Daugherty, et al
FDA Approves EKG Device for Apple Watch, AliveCor news release; 2017 Nov 30
Must Reads in Hypercholesterolemia
LDL-C Lowering with Evolocumab in Patients with PAD, Circulation; ePub 2017 Nov 13; Bonaca, et al
Does Evolocumab Lower Lipoprotein Particles?, Am J Cardiol; ePub 2017 Nov 8; Toth, et al
PCSK9 Inhibition & Neurocognitive Impairment, Circulation; ePub 2017 Nov 16; Mefford, et al
Eligibility for PCSK9 Inhibitors After ACS, J Am Heart Assoc; ePub 2017 Nov 9; Gencer, et al
CV Risk & Statins After MI in Young Adults, J Am Coll Cardiol; ePub 2017 Nov 14; Singh, et al